Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

NCT06262399 · tracked via the Priya Life Science Germany tracker

Sponsor

Intellia Therapeutics

Phase

Observational

Started

2024-04-12

Last updated

2025-11-28

Condition(s) studied

Hereditary Angioedema

Study summary

This is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. A subject has completed or discontinued from an Intellia-sponsored or -supported treatment protocol in which a complete or partial dose of NTLA-2002 was received. 2. A subject has provided informed consent for the LTFU study. 3. A subject is willing to attend study visits, complete protocol-required follow-up schedule, and comply with the study requirements. Exclusion Criteria: None

Primary outcome measure(s)

Incidence of treatment-related Adverse Events (AEs); incidence of treatment-related Serious Adverse Events (SAEs); incidence of treatment-related Adverse Events of Special Interest (AESIs) defined per protocol — up to 15 years

Trial sites (7)

Facility	City	Region
Campbelltown Hospital	Campbelltown	New South Wales
Centre National de Reference - Grenoble	Grenoble	France
Hôpital Claude Huriez	Lille	France
Charite-Universitätsmedizin Berlin	Berlin	Germany
University of Amsterdam Academic Medical Center	Amsterdam	Netherlands
New Zealand Clinical Research	Auckland	New Zealand
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital	Cambridge	United Kingdom

More Intellia Therapeutics trials in Germany

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Active, not recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) Recruiting

NTLA-2002 in Adults With Hereditary Angioedema (HAE) Active, not recruiting

Other trials for the same condition

STOP-HAE: A Phase 3 Study of ADX-324 in HAE Recruiting

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Enrolling by invitation

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Active, not recruiting

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) Active, not recruiting

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06262399 on ClinicalTrials.gov ↗ ← All trials in Germany